AstraZeneca unveils $2 billion manufacturing investment in Maryland
AstraZeneca PLC on Friday announced plans to invest USD2 billion to expand its long-standing manufacturing footprint in Maryland.
The Cambridge, England-based pharmaceuticals company said this includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials.
Friday's announcement is part of AstraZeneca’s USD50 billion investment announced in July and follows a series of US commitments over the past six months, including unveiling a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia and the expansion of the Company's existing manufacturing facility in Coppell, Texas.
UCapital Asset Management LLP or group companies may have commercial relationships with the companies mentioned. This content is not financial advice.
Sign up for free to ask the AI about this article.
Multiples, financials, sentiment and risks in 60 seconds, with live data.